The Patent Finder

An Isolated Nucleic Acid Encoding a Truncated Actriib Fusion Protein

Acceleron Pharma Inc.

A patent family: one line of work, grouped by real continuity rather than by a technology label inferred from titles. 5 of these applications claim priority to application 61/268,420, filed Jun 12, 2009. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleHolderStatusExpiresPatent lifetimeUsedRemainingConfidence
US 8,293,881An Isolated Nucleic Acid Encoding a Truncated Actriib Fusion Protein
In force
 · High confidence
UsedRemaining
Acceleron Pharma Inc.In forceHigh confidence
US 9,745,559A Method for Decreasing the Body Fat Content in a Subject by Administering an Actriib Protein
In force
 · High confidence
Acceleron Pharma Inc.In forceHigh confidence
US 10,358,633Method for Decreasing the Body Fat Content in a Subject by Administering an Actriib Protein
In force
 · Medium confidence
Acceleron Pharma Inc.In forceMedium confidence
US 11,066,654Methods and Compositions for Reducing Serum Lipids
In force
 · Medium confidence
Acceleron Pharma Inc.In forceMedium confidence
US 9,181,533Truncated Actriib-Fc Fusion Protein
In force
 · High confidence
Acceleron Pharma Inc.In forceHigh confidence
Application 17/358,540Truncated Actriib-Fc Fusion Proteins
Abandoned
Abandoned Jan 8, 2024
Acceleron Pharma Inc.AbandonedAbandoned Jan 8, 2024
6 of 6 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
5 of these are in force and held by Acceleron Pharma Inc..
Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited